Expression Pattern of Long Non-Coding RNA Growth Arrest-Specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

Open access

Summary

Background: Long non-coding RNA growth arrest-specific 5 (GAS5) is deregulated in many cancers because of its role in cell growth arrest and apoptosis. Additionally, GAS5 interacts with glucocorticoid receptor, making it a potential pharmacotranscription marker of glucocorticoid (GC) therapy. In this study, we aimed at analysing GAS5 expression in the remission induction therapy phase of childhood acute lympho blastic leukemia (ALL), in which GCs are mandatorily used, and to correlate it with therapy response.

Methods: GAS5 expression was measured in peripheral blood mononuclear cells taken from 29 childhood ALL patients at diagnosis, on day 15 and day 33 of remission induction therapy using RT-qPCR methodology.

Results: Our results have shown interindividual differences in GAS5 expression at all time points. For each ALL patient, GAS5 expression was higher on day 15 in comparison to its level at diagnosis (p<0.0005). On day 33, the level of GAS5 expression decreased in comparison with day 15 (p<0.0005), but it was still significantly higher than at diagnosis for the majority of patients (p=0.001). Patients whose number of blasts on day 8 was below 100 per μL of peripheral blood had a higher GAS5 expression at diagnosis (p=0.016), and lower ratio day 15/diagnosis (p=0.009).

Conclusions: Our results suggest that the expression level of GAS5 could be a potential marker of therapy response in remission induction therapy of childhood ALL.

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030–43.

2. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood all performed by the ALLBFM study group from 1981 to 1995. Leukemia 2000; 14: 2205–22.

3. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014; 32: 174–84.

4. Swartz SL, Dluhy RG. Corticosteroids: Clinical pharmacology and therapeutic use. Drugs 1978; 16: 238–55.

5. Newton R. Molecular mechanisms of glucocorticoid action: What is important? Thorax 2000; 55: 603.

6. Ebrahimi-Rad M, Khatami S, Ansari S, Jalylfar S, Valadbeigi S, Saghiri R. Adenosine deaminase 1 as a biomarker for diagnosis and monitoring of patients with acute lymphoblastic leukemia. J Med Biochem 2018; 37: 128–33.

7. Ratman D, Vanden Berghe W, Dejager L, Libert C, Tavernier J, Beck IM, et al. How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering. Mol Cell Endocrinol 2013; 380: 41–54.

8. Mourtada-Maarabouni M, Hedge VL, Kirkham L, Farzaneh F, Williams GT. Growth arrest in human t-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (gas5). J Cell Sci 2008; 121: 939–46.

9. Milosevic G, Kotur N, Krstovski N, Lazic J, Zukic B, Stankovic B, Janic D, Katsila T, Patrinos PG, Pavlovic S, Dokmanovic L. Variants in TPMT, ITPA, ABCC4 and ABCB1 henes as predictors of 6-mercaptopurine induced toxicity in children with acute lymphoblastic leukemia. J Med Biochem 2018; 37: 320–7.

10. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia consortium study. J. Clin Oncol 2010; 28: 648–54.

11. Chen QN, Wei CC, Wang ZX, Sun M. Long non-coding RNAs in anti-cancer drug resistance. Oncotarget 2017; 8: 1925–36.

12. Carter G, Miladinovic B, Patel AA, Deland L, Mastorides S, Patel NA. Circulating long noncoding RNA GAS5 levels are correlated to prevalence of type 2 diabetes mellitus. BBA clinical 2015; 4: 102–7.

13. Li W, Huang K, Wen F, Cui G, Guo H, Zhao S. Genetic variation of lncRNA GAS5 contributes to the development of lung cancer. Oncotarget 2017; 8: 91025–29.

14. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195–208.

15. Wen Q, Liu Y, Lyu H, Xu X, Wu Q, Liu N, et al. Long Non-coding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer 2017; 27: 1096–108.

16. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007; 12: 215–29.

17. Lammens T, Durinck K, Wallaert A, Speleman F, Van Vlierberghe P. Long non-coding RNAs in leukemia: Biology and clinical impact. Curr Opin Hematol 2017; 24: 353–8.

18. Wang X, Zhu B, Huang Z, Chen L, He Z, Zhang H. microRNAs as biomarkers in leukemia. Stem Cell Investigation 2014; 1: 11.

19. Garabedian MJ, Logan SK. Glucocorticoid receptor DNA binding decoy is a gas. Science signaling 2010; 3: pe5.

20. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013; 1832: 1613–23.

21. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, et al. Downregulation of GAS5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 2013; 354: 891–6.

22. Lucafo M, Di Silvestre A, Romano M, Avian A, Antonelli R, Martelossi S, et al. Role of the long non-coding RNA growth arrest-specific 5 in glucocorticoid response in children with inflammatory bowel disease. Basic Clin Pharmacol Toxicol 2018; 122: 87–93.

23. Gunnarsson R, Dilorenzo S, Lundin-Strom KB, Olsson L, Biloglav A, Lilljebjorn H, et al. Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric bcell precursor acute lymphoblastic leukemia. Leukemia 2018; 32: 2117–25.

24. Yan H, Zhang DY, Li X, Yuan XQ, Yang YL, Zhu KW, et al. Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic re constitution. Leuk. Lymphoma 2017; 58: 1948–57.

25. Xin Y, Zeng L. Long non-coding RNA growth arrestspecific transcript 5 in tumor biology. Oncol Lett 2015; 10: 1953–58.

26. Lucafo M, De Iudicibus S, Di Silvestre A, Pelin M, Candussio L, Martelossi S, et al. Long noncoding RNA GAS5: A novel marker involved in glucocorticoid response. Curr Mol Med 2015; 15: 94–9.

27. Frankfurt O, Rosen S T. Mechanisms of glucocorticoidinduced apoptosis in hematologic malignancies: Updates. Curr Opin Oncol 2004; 16: 553–63.

28. Hong S-Y, Yoon W-H, Park J-H, Kang S-G, Ahn J-H, Lee TH. Involvement of two NF-kb binding elements in tumor necrosis factor α-, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 2000; 275: 18022–28.

29. Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002; 143: 3866–74.

30. Wen L-P, Madani K, Fahrni J, Duncan SR, Rosen G. Dexamethasone inhibits lung epithelial cell apoptosis induced by IFN-gamma and Fas. Journal 1997; 273: L921–9.

31. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Non-coding RNA GAS5 is a growth arrest- and starvationassociated repressor of the glucocorticoid receptor. Science signaling 2010; 3: ra8.

32. Deveraux QL, Reed JC. Iap family proteins – suppressors of apoptosis. Genes Dev 1999; 13: 239–52.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2017: 1.378
5-year IMPACT FACTOR: 0.704



CiteScore 2017: 1.05

SCImago Journal Rank (SJR) 2017: 0.307
Source Normalized Impact per Paper (SNIP) 2017: 0.532

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 79 79 27
PDF Downloads 68 68 18